IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer
Ontology highlight
ABSTRACT: We identified IGF2BP1 as a marker of the C5 molecular subtype of high-grade ovarian carcinoma (HG-SOC). IGF2BP1 promotes SRC activity and ERK2 expression enhancing the tolerance towards SRC- and MEK-directed inhibitors saracatinib and selumetib. Combination treatment overcomes IGF2BP1-promoted resistance.
ORGANISM(S): Homo sapiens
PROVIDER: GSE147980 | GEO | 2020/08/24
REPOSITORIES: GEO
ACCESS DATA